Following the arrival of the coronavirus in the U.S., people with cancer and their doctors are adjusting to new ways of doing things while continuing to seek and provide cancer care.
by Kate Yandell
Cancer drug repositories that accept unused drugs could provide an affordable source of medications for patients in need, while also providing patients left with extra drugs a way to give back.
by Jon Kelvey
Cancer patients and their families share stories of fear, love and uncertainty as they find new ways to support each other.
by Jen Tota McGivney
Responding to the coronavirus, patient advocates and nonprofits expand existing outreach initiatives and launch new ones.
by Marci A. Landsmann
FORWARD LOOK
Studies provide little evidence to support this claim.
by Stephen Ornes
Get Involved
A mother whose son was diagnosed with Burkitt leukemia works to improve access to mental health services for teenagers.
by Elizabeth Rosto Sitko
Survivor Profile
Mark Good uses every avenue to spread the news about prostate cancer.
by Lindsey Konkel
Advocacy in Action
Two mothers, each with a son who died of brain cancer, worked together to increase awareness and acceptance of tumor tissue donation.
by Esther Landhuis
POLICY MATTERS
Cancer outcomes are changing for the better, but advances are not affecting all patients equally.
by Brian Rivers, PhD
The National Cancer Institute and the Food and Drug Administration have provided guidance for managing clinical trials amid the spread of the novel coronavirus. Cancer centers are making changes to care for some patients enrolled in trials.
by Anna Azvolinsky
COVID-19 slowed or stopped enrollment in some cancer clinical trials.
Data shed light on risk factors for death among people with cancer infected with the coronavirus.
I have brain cancer, and my wife is a health care worker. These are some questions we had to consider leading up to and after her diagnosis with COVID-19.
by Adam Hayden
Identifying patients whose cancers will have durable responses to checkpoint inhibitors can guide treatment.
The FDA has expanded the use of the PARP-targeted therapeutic olaparib to include the treatment of certain patients with metastatic prostate cancer.
Bladder cancer is the sixth most prevalent cancer in the United States and has a high rate of recurrence.
Handle With Care
donate to the AACR